Belite Bio, Inc (BLTE) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Be Light Bio (BLTE) Q1 2026: SG&A Rises 179% as Commercial Launch Readiness Accelerates
  June 17, 2026
• Belite Bio (BLTE) Q2 2025: Dragon Phase 3 Nears 24-Month Endpoint, FDA Single-Study Approval Path in Focus
  June 16, 2026
• Be Light Bio (BLTE) Q3 2025: $140M Capital Infusion Extends Runway for Global Tinlaraban Launch
  June 16, 2026
• BeLight Bio (BLTE) Q4 2025: Cash Surges to $773M as Phase 3 Stargardt Program Hits 36% Lesion Reduction
  June 15, 2026
• Be Light Bio (BLTE) Q1 2025: DRAGON Phase 3 DSMB Endorsement Signals Regulatory Momentum
  July 03, 2025
• Be Light Bio (BLTE) Q3 2024: R&D Spend Drops $1.9M as Stargardt’s and GA Trials Hit Key Enrollment Milestones
  November 12, 2024
• Be Light Bio (BLTE) Q2 2024: R&D Spend Rises 65% as Dragon and Phoenix Trials Hit Key Milestones
  August 12, 2024
• BeLiveBio (BLTE) Q1 2024: Cash Position Surges to $95M as Phase 3 Enrollment Hits Milestones
  May 14, 2024
• Be Light Bio (BLTE) Q4 2024: Phase 3 Dragon Trial DSMB Endorsement Signals Accelerated Path for Teneraband
  March 12, 2024
• Beelight Bio (BLTE) Q3 2023: R&D Spend Jumps $7.5M as Phase III Enrollment Hits Key Milestones
  November 14, 2023

Browse all companies